Hypogonadism, Male
Conditions
Keywords
Hypogonadism, Nebido, Testosterone, Observational Study
Brief summary
This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism. The benefit and safety of Nebido have already been thoroughly evaluated through well controlled clinical trials. The main purpose of this observational study is to confirm the established safety profile of Nebido in daily clinical practice.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Interventions
DRUGTestosterone Undecanoate (Nebido, BAY86-5037)
Patients from routine practice
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male hypogonadal patients eligible for long-term testosterone therapy who have newly been prescribed Nebido® in accordance with the terms of the marketing authorization
Exclusion criteria
* Patients presenting with contraindications as stated in the product information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events, adverse drug reactions, patient reported tolerability | during 4 injection intervals |
Secondary
| Measure | Time frame |
|---|---|
| Change in subjective assessment of the patient (overall sexual desire/libido, vigor/vitality, mood, ability to concentrate) from baseline to end of observation | after 4 injection intervals |
| Change in intensity of symptoms or disorders associated with low testosterone (hot flushes or excessive sweating, sleep disturbances, decreased physical strength and erectile dysfunction) from baseline to end of observation | after 4 injection intervals |
| Patient reported outcome at end of observation (satisfaction with current androgen therapy, comparison to previous androgen therapy, if applicable) | after 4 injection intervals |
| Change in laboratory values (total testosterone, estradiol, SHGB, FSH, LH) from baseline to end of observation | after 4 injection intervals |
| Vital signs and anthropometric measurements (Blood pressure, heart rate, weight and waist circumference) | during 4 injection intervals |
| Laboratory values (PSA, hemoglobin, hematocrit, HbA1C, T-chol, HDL-chol, LDL-chol, triglycerides) | during 4 injection intervals |
| Digital rectal examination | during 4 injection intervals |
| Treatment continuation rate | after 4 injection intervals |
Countries
Australia, Austria, Bulgaria, Colombia, Czechia, Estonia, Germany, Hong Kong, Indonesia, Italy, Jordan, Kazakhstan, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, North Macedonia, Philippines, Romania, Russia, Saudi Arabia, Singapore, Slovenia, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom
Outcome results
None listed